Trials / Unknown
UnknownNCT05536427
Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma
An Open-Label, Multi-Center, Multiple-Dose, Dose-Escalation and Dose-Expansion, Investigator-Initiated Phase I Clinical Study to Observe and Evaluate the Tolerability, Safety, Pharmacodynamics, and Preliminary Efficacy of IPM001 Injection in the Treatment of Progressive Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, safety and effects of IPM001 injection on human hepatocellular carcinoma are going to be investigated, IPM001 is a multiple tumor-associated antigen (TAA) and neoantigen/tumor-specific antigen (TSA) sensitized autoimmune cell injection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IPM001 | IPM001 will be used against tumor cells |
Timeline
- Start date
- 2022-10-01
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
- First posted
- 2022-09-10
- Last updated
- 2023-03-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05536427. Inclusion in this directory is not an endorsement.